Common-Size Balance Sheet: Assets
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The composition of assets has undergone significant shifts between 2021 and 2025. A notable trend is the substantial decrease in the proportion of current assets relative to total assets, while the share of non-current assets has increased correspondingly. This suggests a strategic shift towards longer-term investments and a potential decrease in short-term liquidity focus.
- Current Assets
- Current assets, representing 71.18% of total assets in 2021, experienced a decline to 43.68% by 2025. This decrease is primarily driven by a significant reduction in cash and cash equivalents, which fell from 50.59% to 19.83% over the same period. Accounts receivable remained relatively stable, fluctuating between 6.88% and 8.46% of total assets. Inventories exhibited a gradual increase, rising from 2.63% to 6.58%, indicating a potential build-up in stock. The proportion of prepaid expenses and other current assets also decreased slightly.
- Non-Current Assets
- Non-current assets increased from 28.82% of total assets in 2021 to 56.32% in 2025. This growth is largely attributable to increases in deferred tax assets and long-term marketable securities. Deferred tax assets grew substantially, from 6.96% to 11.30%. Long-term marketable securities emerged as a significant component, increasing from a negligible amount in 2021 to 22.28% in 2025. Property and equipment, net, and goodwill experienced moderate declines as percentages of total assets. Other intangible assets decreased significantly from 2023 to 2025.
- Cash Position
- The company’s cash position, as a percentage of total assets, experienced a dramatic decrease. From a high of 50.59% in 2021, it fell to 19.83% in 2025. This suggests a significant deployment of cash into other assets, particularly long-term marketable securities and deferred tax assets. The decrease in cash is the most prominent change observed in the asset composition.
- Asset Mix Shift
- The asset mix has shifted considerably from a cash-heavy profile in 2021 to a more diversified structure in 2025, with a greater emphasis on long-term investments and deferred tax assets. The increase in operating lease assets from 2.46% to 6.09% also contributes to this diversification. This shift may indicate a change in the company’s long-term strategy, potentially focusing on growth initiatives and tax optimization.
Overall, the asset composition demonstrates a strategic reallocation of resources over the five-year period. The reduction in liquid assets, coupled with the increase in long-term investments and deferred tax assets, suggests a long-term oriented financial strategy.